> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Genentech Wins FDA Priority Review Voucher
- URL: https://www.fdaweb.com/genentech-wins-fda-priority-review-voucher/
- Published: 2020-08-24T12:00:00.000Z
- Updated: 2026-09-14T16:26:13.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5147497

FDA has issued a priority review voucher to Genentech for gaining approval of a rare pediatric disease product application — Evrysdi (risdiplam), indicated for treating patients two months of age and older with spinal muscular atrophy, a rare and often fatal genetic disease affecting muscle strength and movement. To view the notice, click [here](https://s3.amazonaws.com/public-inspection.federalregister.gov/2020-18648.pdf?ref=fdaweb.com).